Inhibrx Biosciences Cash Flow Statement (2023-2025) | INBX

Cash Flow Statement Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Operating Activities
Net Income -48.92M-51.79M-91.97M-78.71M1,858.01M-43.86M-47.87M-43.31M-28.65M-35.26M
Share-based Compensation 6.53M6.43M6.40M46.17M2.96M2.98M2.45M2.77M3.17M
Gains from Investment Securities -0.00M1.64M1.42M2.16M-0.03M0.12M-0.03M0.01M0.02M
Cash from Operations -54.24M-56.82M-63.05M-57.36M-30.28M-43.72M-35.90M-29.95M-33.82M
Depreciation, Depletion & Amortization
Amortization of Deferred Charges 1.24M1.25M1.24M0.82M0.53M0.63M0.64M
Depreciation & Amortization (CF) 0.29M0.30M0.30M0.36M0.47M0.76M0.69M0.68M0.66M0.58M
Change in Working Capital
Change in Receivables 0.00M0.45M0.61M-0.27M-0.77M0.04M-0.18M0.87M-0.00M
Change in Account Payables -1.59M2.91M4.05M17.42M-0.45M-3.12M-0.35M-0.60M-1.52M
Change in Accured Expenses 6.35M17.39M8.03M21.82M6.03M2.88M-4.30M-1.51M
Investing Activities
Capital Expenditures 0.57M3.44M1.12M1.22M0.25M0.02M0.02M0.01M
Cash from Investing Activities -0.81M-3.44M-1.12M-1.22M-0.25M-0.02M-0.02M-0.01M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt Issuances 99.97M
Change in Capital Stock
Shares Issued 198.79M38.73M32.95M0.35M
Misc.
Cash from Financing Activities 199.89M0.86M38.73M32.95M99.84M0.35M
Change in Cash 144.84M-59.40M-25.44M-25.62M-30.53M-43.74M63.92M-29.95M-33.48M
Beginning Cash Balance -144.84M337.33M25.44M252.52M226.86M196.33M152.60M216.55M186.58M
Free Cash Flow -54.81M-60.26M-64.17M-58.57M-30.53M-43.74M-35.92M-29.95M-33.83M
Net Cash Flow 144.84M-59.40M-25.44M-25.62M-30.53M-43.74M63.92M-29.95M-33.48M